Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Adverse events in SAD cohorts. Those TEAEs that occurred in more than one cohort in the SAD study are listed

From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

MedDRA Preferred Term

Placebo

BAN2401 (mg/kg)

(N = 12) (%)

0.1 (N = 6) (%)

0.3 (N = 6) (%)

1 (N = 6) (%)

3 (N = 6) (%)

10 (N = 6) (%)

15 (N = 6) (%)

Total (N = 36) (%)

Subjects with any TEAE

8 (66.7)

6 (100.0)

1 (16.7)

3 (50.0)

3 (50.0)

2 (33.3)

5 (83.3)

20 (55.6)

Dizziness

1 (8.3)

2 (33.3)

0

1 (16.7)

0

0

0

3 (8.3)

Fatigue

1 (8.3)

0

0

0

0

0

2 (33.3)

2 (5.6)

Sinusitis

0

1 (16.7)

0

0

1 (16.7)

0

0

2 (5.6)

Asymptomatic ARIA-H

0

0

1 (16.7)

1 (16.7)

0

0

0

2 (5.6)

  1. For each row category, a subject with 2 or more TEAEs with the same PT in that category was counted only once. A TEAE is defined as an AE which started after first dose and within 90 days of last dose.
  2. AE adverse event, MAD multiple ascending dose, MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, SAD single ascending dose, TEAE treatment emergent adverse event
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193